NCT04198766 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT04198766
Title	Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Inhibrx Biosciences, Inc
Indications	renal cell carcinoma lung non-small cell carcinoma nasopharynx carcinoma transitional cell carcinoma head and neck squamous cell carcinoma Advanced Solid Tumor melanoma gastric adenocarcinoma uveal melanoma gastroesophageal adenocarcinoma
Therapies	INBRX-106 INBRX-106 + Pembrolizumab Carboplatin + INBRX-106 + Nab-paclitaxel + Pembrolizumab Pembrolizumab Cisplatin + INBRX-106 + Pembrolizumab + Pemetrexed Disodium Carboplatin + INBRX-106 + Pembrolizumab + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	USA

Additional content available in CKB BOOST